The Third Xiangya Hospital of Central South University
Welcome,         Profile    Billing    Logout  
 0 Trials 
8 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zhang, Jianjun
NCT06353126: DEB-TACE Prior to Liver Transplantation in the Treatment of HCC

Recruiting
4
40
RoW
DEB-TACE
RenJi Hospital, Boston Scientific Corporation
Liver Cancer
07/25
07/27
HLX10-020-SCLC302, NCT05353257 / 2022-002226-27: A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

Active, not recruiting
3
511
Europe, US, RoW
HLX10, Serplulimab, carboplatin/cisplatin-etoposide, Thoracic radiotherapy, Placebo, Prophylactic Cranial Irradiation (PCI)
Shanghai Henlius Biotech, Shanghai Henlius Biotech, Inc.
Limited-Stage Small Cell Lung Cancer
07/25
12/26
HARMONi-3, NCT05899608: Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

Recruiting
3
1080
Canada, US
Ivonescimab Injection, Pembrolizumab Injection
Summit Therapeutics
Non-Small Cell Lung Cancer
12/27
12/28
CLINCH, NCT05718895: A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors

Recruiting
1
156
RoW
ATG-022
Antengene Biologics Limited
Advanced/Metastatic Solid Tumors
06/26
06/26
Shen, Lu
NCT05908695: An Efficacy and Safety Study of Sodium Oligomannate (GV-971) for the Treatment of Alzheimer's Disease

Recruiting
4
1312
RoW
GV-971, Placebo
Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
Alzheimer's Disease
06/29
12/29
TRAILRUNNER-ALZ 3, NCT06653153: A Study of Remternetug (LY3372993) in Early Alzheimer's Disease

Recruiting
3
1200
Europe, Canada, Japan, US, RoW
Remternetug, LY3372993, Placebo
Eli Lilly and Company
Alzheimer's Disease
04/29
10/30
NCT06010693: A Study of Daridorexant in Chinese Patients With Insomnia Disorder

Completed
3
206
RoW
Daridorexant, Placebo
Jiangsu Simcere Pharmaceutical Co., Ltd.
Insomnia Disorder
04/24
05/24
TRAILBLAZER-ALZ 5, NCT05508789: A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease

Recruiting
3
1500
Europe, RoW
Donanemab, (LY3002813), Placebo
Eli Lilly and Company
Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
04/27
04/27

Download Options